What is Dr. Zubair Khalid's research focus?

Dr. Zubair Khalid specializes in molecular virology, mRNA vaccine development, and computational biology, with a focus on avian pathogens like IBDV and Avian Reovirus.

Where is Dr. Zubair Khalid currently working?

Dr. Zubair Khalid is a Postdoctoral Research Associate at the University of Maryland (UMD), specifically within the Department of Animal and Avian Sciences.

Wnt Signalling Pathway in Cancer: Mechanisms and Therapeutic Targets

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Introduction to Wnt Signalling Pathway in Cancer

The Wnt signalling pathway is a highly conserved cell-to-cell communication system that governs fundamental processes including embryonic development, cell proliferation, differentiation, polarity, and migration. In adult organisms, Wnt signalling is largely quiescent, reactivated only in specific contexts such as tissue regeneration, stem cell maintenance, and wound healing. When this tightly regulated pathway becomes constitutively active, it drives oncogenic transformation across a broad spectrum of human malignancies, most notably colorectal cancer, hepatocellular carcinoma, and certain leukaemias.

The name "Wnt" derives from a fusion of two discovery streams: the wingless gene in Drosophila melanogaster and the Int-1 gene in mouse mammary tumours. This dual origin reflects the pathway's dual nature—essential developmental morphogen and potent oncogene. Understanding the molecular mechanics of Wnt signalling is therefore not merely an academic exercise; it is central to comprehending how a single pathway can orchestrate both the exquisite precision of embryogenesis and the chaotic dysregulation of cancer.

Overview of Wnt Ligands and Receptors

Wnt ligands are secreted glycoproteins, approximately 40 kDa in size, modified by lipid palmitoylation—a post-translational addition of palmitoleic acid to a conserved cysteine residue. This lipid modification is catalysed by the enzyme Porcupine, an O-acyltransferase residing in the endoplasmic reticulum. The lipid moiety is essential for Wnt secretion and for its interaction with receptors, but it also renders Wnt proteins hydrophobic and poorly soluble in aqueous environments, complicating their biochemical study.

Mammals express 19 Wnt ligands and 10 Frizzled (FZD) receptors. Frizzled proteins are seven-pass transmembrane receptors with an extracellular cysteine-rich domain (CRD) that directly binds Wnt ligands. Signal transduction requires co-receptors: the single-pass transmembrane proteins LRP5/6 (low-density lipoprotein receptor-related protein 5 and 6) for canonical signalling, or ROR1/ROR2 and RYK for non-canonical pathways. The sheer combinatorial complexity of 19 ligands × 10 receptors × multiple co-receptors generates enormous signalling diversity, which explains how a single pathway can elicit context-dependent cellular responses.

Historical Discovery and Importance

The Wnt pathway's cancer connection emerged in 1982 when Nusse and Varmus identified Int-1 as a proto-oncogene activated by mouse mammary tumour virus insertion. Concurrently, wingless was characterised as a segment polarity gene in Drosophila. The convergence of these fields in the late 1980s established the Wnt gene family. A pivotal moment arrived in 1991 with the discovery that APC (adenomatous polyposis coli) mutations cause familial adenomatous polyposis (FAP), a hereditary colorectal cancer syndrome. Subsequent work revealed that APC is a core negative regulator of β-catenin, the central effector of canonical Wnt signalling. This placed Wnt signalling at the heart of colorectal tumorigenesis and catalysed three decades of intensive investigation.

Canonical Wnt/β-Catenin Signalling Mechanism

The canonical Wnt pathway, also termed Wnt/β-catenin signalling, is the best-characterised branch and the one most frequently implicated in cancer. Its central logic is simple: in the absence of Wnt ligand, β-catenin is constitutively degraded; in the presence of Wnt ligand, degradation is halted, allowing β-catenin to accumulate and translocate to the nucleus, where it drives transcriptional programmes.

The Destruction Complex: APC, Axin, GSK3β, CK1

In the resting state, cytoplasmic β-catenin is sequestered by a multi-protein destruction complex. The scaffold proteins Axin and APC (adenomatous polyposis coli) form the structural backbone, bringing together two constitutively active kinases: casein kinase 1α (CK1α) and glycogen synthase kinase 3β (GSK3β).

The destruction process proceeds in ordered steps:

Priming phosphorylation: CK1α phosphorylates β-catenin at serine residue 45 (Ser45).
Processive phosphorylation: GSK3β then phosphorylates β-catenin at threonine 41 (Thr41), serine 37 (Ser37), and serine 33 (Ser33). These phosphorylation events create a phosphodegron motif.
Ubiquitination: The E3 ubiquitin ligase β-TrCP (beta-transducin repeat containing protein) recognises the phosphodegron and conjugates ubiquitin chains to β-catenin.
Proteasomal degradation: Polyubiquitinated β-catenin is targeted to the 26S proteasome and degraded. The half-life of β-catenin in unstimulated cells is approximately 90 minutes.

When a Wnt ligand binds to Frizzled and LRP5/6, a cascade of events disrupts the destruction complex. The key molecular event is the phosphorylation of LRP6 by GSK3β and CK1γ at its cytoplasmic PPPSPxS motifs. This phosphorylation recruits Axin to the receptor complex, effectively titrating Axin away from the destruction complex. Simultaneously, the protein Dishevelled (DVL) is recruited to Frizzled and polymerises, further promoting destruction complex disassembly. The net result is that β-catenin phosphorylation ceases, and newly synthesised β-catenin escapes degradation.

Nuclear Functions of β-Catenin

Accumulated β-catenin translocates to the nucleus, where it functions as a transcriptional co-activator. It does not bind DNA directly; instead, it interacts with the T-cell factor/lymphoid enhancer factor (TCF/LEF) family of transcription factors. In the absence of β-catenin, TCF/LEF proteins are bound to DNA and repress transcription by recruiting co-repressors such as Groucho/TLE. β-catenin binding displaces these repressors and recruits co-activators including CBP/p300, BCL9, and Pygopus.

The transcriptional output of β-catenin/TCF is substantial. Direct target genes include:

Proliferation regulators: MYC, CCND1 (cyclin D1)
Stem cell markers: LGR5, SOX9, ASCL2
Survival factors: Survivin (BIRC5), MCL1
Invasion and metastasis genes: MMP7 (matrix metalloproteinase 7), SNAIL, VEGFA

This transcriptional programme explains why aberrant Wnt activation is so potently oncogenic: it simultaneously drives proliferation, blocks apoptosis, maintains stemness, and promotes invasion. The crosstalk with other oncogenic pathways, such as the PI3K AKT Pathway and the MAPK Pathway, further amplifies these effects in many cancers.

Non-Canonical Wnt Signalling Pathways

Not all Wnt signalling operates through β-catenin. The non-canonical pathways are β-catenin-independent and are broadly divided into the Wnt/planar cell polarity (PCP) pathway and the Wnt/Ca²⁺ pathway. These pathways are critical for cell polarity, migration, and cytoskeletal organisation, and their dysregulation contributes to cancer metastasis and invasion.

Wnt/PCP Pathway and Cell Polarity

The Wnt/PCP pathway regulates cell polarity within the plane of a tissue—for example, the orientation of hair cells in the inner ear or the uniform alignment of epithelial cells. In this pathway, Wnt ligands (typically Wnt5a, Wnt11) bind Frizzled receptors and co-receptors ROR1/ROR2, activating the small GTPases RhoA and Rac1 via Dishevelled.

The signalling cascade proceeds as follows:

Wnt binding to Frizzled/ROR2 recruits Dishevelled to the membrane.
Dishevelled activates the guanine nucleotide exchange factors (GEFs) that load GTP onto RhoA and Rac1.
RhoA activates Rho-associated kinase (ROCK), promoting actin polymerisation and actomyosin contractility.
Rac1 activates c-Jun N-terminal kinase (JNK), which phosphorylates transcription factors such as c-Jun and ATF2.

In cancer, aberrant PCP signalling promotes epithelial-to-mesenchymal transition (EMT), a process where epithelial cells lose cell-cell adhesion and acquire migratory, mesenchymal characteristics. Elevated ROR2 expression has been documented in melanoma, osteosarcoma, and renal cell carcinoma, where it correlates with invasive behaviour. The PCP pathway also influences the orientation of cell division, potentially contributing to the disorganised tissue architecture characteristic of tumours.

Wnt/Ca²⁺ Pathway and Cell Migration

The Wnt/Ca²⁺ pathway involves Wnt ligands (Wnt5a, Wnt3a) stimulating Frizzled receptors, leading to G-protein-mediated activation of phospholipase C (PLC). PLC cleaves phosphatidylinositol 4,5-bisphosphate (PIP₂) into inositol 1,4,5-trisphosphate (IP₃) and diacylglycerol (DAG). IP₃ triggers calcium release from the endoplasmic reticulum, while DAG activates protein kinase C (PKC). Downstream effectors include calcium/calmodulin-dependent kinase II (CaMKII) and the phosphatase calcineurin, which activates the transcription factor NFAT.

The Wnt/Ca²⁺ pathway regulates cell migration, adhesion, and tissue separation during development. In cancer, its role is context-dependent. In melanoma, Wnt5a signalling through the Ca²⁺ pathway promotes invasion and metastasis. However, in some contexts, non-canonical Wnt signalling can antagonise canonical β-catenin signalling, suggesting a complex interplay where the balance between pathways determines the oncogenic outcome. This cross-talk between canonical and non-canonical branches is an active area of investigation, as therapeutic strategies targeting one branch may inadvertently activate the other.

Genetic and Epigenetic Alterations in Cancer

The Wnt pathway is dysregulated in cancer through multiple mechanisms: gain-of-function mutations in positive regulators, loss-of-function mutations in negative regulators, and epigenetic silencing of pathway inhibitors. The specific alterations vary by cancer type but converge on the same endpoint—constitutive β-catenin stabilisation and transcriptional activation.

APC Mutations in Colorectal Cancer

APC is mutated in approximately 80% of sporadic colorectal cancers and is the germline cause of familial adenomatous polyposis. The APC protein is a large (312 kDa) multifunctional scaffold that contains multiple β-catenin-binding repeats and Axin-binding domains. Most cancer-associated mutations are nonsense or frameshift mutations that produce truncated proteins lacking the C-terminal β-catenin-binding and Axin-binding regions.

The functional consequence is profound: truncated APC cannot properly assemble the destruction complex, so β-catenin phosphorylation and degradation are impaired. Importantly, the mutation spectrum is not random—the "mutation cluster region" (MCR) between codons 1286 and 1513 is preferentially affected. This region encodes the 20-amino-acid β-catenin-binding repeats, and its deletion leaves the protein unable to promote β-catenin degradation but still able to bind β-catenin weakly, creating a dominant-negative effect.

The "two-hit" hypothesis applies to APC in colorectal cancer: both alleles must be inactivated. The first hit is often a point mutation, while the second is typically loss of heterozygosity (LOH)—loss of the entire wild-type allele. This biallelic inactivation is an early event in colorectal tumorigenesis, occurring in adenomas before malignant transformation.

CTNNB1 Mutations and β-Catenin Stabilisation

CTNNB1, the gene encoding β-catenin, is mutated in a subset of cancers lacking APC mutations, including approximately 15% of hepatocellular carcinomas, 10% of colorectal cancers, and a significant fraction of desmoid tumours and hepatoblastomas. These mutations cluster in exon 3, which encodes the N-terminal domain containing the GSK3β and CK1α phosphorylation sites.

Missense mutations at Ser33, Ser37, Thr41, or Ser45, or in-frame deletions encompassing these residues, abolish phosphorylation and thereby prevent β-TrCP recognition and ubiquitination. The mutant β-catenin is metabolically stable, accumulates in the cytoplasm, and constitutively translocates to the nucleus. Importantly, these mutations are heterozygous—the mutant allele acts dominantly, and the wild-type allele is often retained. This contrasts with APC, where both alleles must be inactivated, reflecting the different stoichiometries of the two proteins in the destruction complex.

Epigenetic Silencing of Wnt Antagonists

Beyond mutations, epigenetic mechanisms silence several classes of Wnt pathway inhibitors. The secreted Frizzled-related proteins (SFRPs) comprise a family of five proteins (SFRP1-5) that sequester Wnt ligands, preventing their interaction with Frizzled receptors. The Dickkopf (DKK) family (DKK1-4) inhibits canonical signalling by binding LRP5/6 and promoting its internalisation. Wnt inhibitory factor 1 (WIF-1) similarly binds Wnt ligands.

In many cancers, the promoters of SFRP1, SFRP2, SFRP4, SFRP5, DKK1, DKK3, and WIF1 are hypermethylated at CpG islands, leading to transcriptional silencing. This epigenetic inactivation is particularly well documented in colorectal cancer, where SFRP methylation is an early event detectable in premalignant adenomas. The functional consequence is that even without mutations in APC or CTNNB1, Wnt signalling becomes hyperactivated because the endogenous brakes are removed.

The reversibility of epigenetic silencing has therapeutic implications: DNA methyltransferase inhibitors such as 5-azacytidine can reactivate SFRP expression and suppress Wnt signalling in experimental models. This provides a rationale for combining epigenetic therapies with conventional cytotoxic agents in Wnt-driven cancers.

Wnt Signalling in Cancer Stem Cells and Tumour Microenvironment

Wnt signalling is not merely a driver of tumour initiation; it also maintains the cancer stem cell (CSC) population and shapes the tumour microenvironment to support tumour growth and metastasis.

Cancer Stem Cell Maintenance

Cancer stem cells are a subpopulation of tumour cells with the capacity for self-renewal and differentiation, properties that drive tumour heterogeneity, therapy resistance, and recurrence. Wnt signalling is a master regulator of stem cell identity in multiple tissues, including the intestinal crypt, hair follicle, and mammary gland. Unsurprisingly, the same pathway maintains CSCs in Wnt-driven cancers.

The intestinal crypt provides the clearest example. LGR5 (leucine-rich repeat-containing G-protein coupled receptor 5) marks intestinal stem cells and is itself a Wnt target gene. In colorectal cancer, LGR5-positive cells represent the CSC population, and ablation of these cells causes tumour regression. The Wnt pathway maintains CSC self-renewal by sustaining expression of stem cell transcription factors such as SOX9 and ASCL2, while simultaneously suppressing differentiation programmes.

Therapeutic resistance is intimately linked to CSC maintenance. Because Wnt signalling promotes quiescence or slow cycling in some CSC populations, these cells are less sensitive to conventional chemotherapies that target rapidly dividing cells. This explains the high rate of relapse in Wnt-driven cancers and motivates the development of Wnt inhibitors as a strategy to eliminate the CSC reservoir.

Wnt in Angiogenesis and Immune Evasion

Wnt signalling influences the tumour microenvironment through multiple mechanisms. One of the most important is angiogenesis—the formation of new blood vessels. β-catenin directly transactivates VEGFA (vascular endothelial growth factor A), a key pro-angiogenic factor. Additionally, Wnt signalling in endothelial cells promotes their proliferation and vessel branching. Tumour-associated endothelial cells often show activated Wnt signalling, and inhibiting this pathway can normalise tumour vasculature and improve drug delivery.

Wnt signalling also modulates the immune microenvironment. Tumour cells with active Wnt signalling secrete factors that suppress anti-tumour immunity. Notably, β-catenin activation in melanoma cells leads to reduced expression of the chemokine CCL5 and the T-cell chemoattractant CXCL10, resulting in exclusion of CD8⁺ T cells from the tumour. This "cold" tumour phenotype is associated with poor response to immune checkpoint inhibitors. Conversely, inhibiting Wnt signalling can restore T-cell infiltration and sensitise tumours to immunotherapy.

The interplay between Wnt signalling and other inflammatory pathways, including Nfkb Pathway, further shapes the tumour microenvironment. Wnt activation can suppress NF-κB-dependent pro-inflammatory cytokine production in some contexts, while in others, NF-κB signalling upregulates Wnt ligands, creating a feed-forward loop that sustains tumour progression.

Methods to Study Wnt Signalling in Cancer

Investigating Wnt signalling requires a combination of biochemical, cell biological, and genetic approaches. Each method provides complementary information about pathway activity, localisation, and function.

Luciferase Reporter Assays

The TOP/FOP flash reporter system is the gold standard for measuring canonical Wnt transcriptional activity. The TOPflash reporter contains multiple TCF/LEF binding sites upstream of a minimal promoter driving firefly luciferase. The FOPflash reporter contains mutated TCF/LEF binding sites and serves as a negative control. Cells are co-transfected with the reporter and a constitutively expressed Renilla luciferase for normalisation.

The assay protocol typically involves:

Seed cells in 24-well plates at 70% confluence.
Transfect with TOPflash or FOPflash (100 ng/well) plus Renilla (10 ng/well) using a lipid-based reagent.
After 24 hours, treat with Wnt3a-conditioned medium or a pathway inhibitor.
Lyse cells after 6-24 hours in passive lysis buffer.
Measure firefly and Renilla luciferase activities using a luminometer with dual-injection.
Calculate the TOP/FOP ratio to determine specific Wnt transcriptional activity.

This assay is rapid, quantitative, and amenable to high-throughput screening for Wnt pathway modulators.

Immunohistochemistry for β-Catenin

Immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded tissue sections provides spatial information about β-catenin localisation. In normal tissues, β-catenin is predominantly membranous, where it participates in adherens junctions. In Wnt-activated cancers, β-catenin accumulates in the cytoplasm and nucleus.

The staining pattern is diagnostically informative:

Staining Pattern	Interpretation
Membranous only	Normal or inactive Wnt signalling
Membranous + cytoplasmic	Partial pathway activation
Nuclear (with or without cytoplasmic)	Active canonical Wnt signalling
Loss of membranous staining	EMT or loss of cell adhesion

For colorectal cancer diagnosis, nuclear β-catenin staining is a hallmark of APC or CTNNB1 mutations. The antibody commonly used is the mouse monoclonal clone β-catenin-1 (dilution 1:100-1:200), with antigen retrieval performed in citrate buffer (pH 6.0) at 95°C for 20 minutes.

Zebrafish and Mouse Models

Genetic models provide functional evidence for Wnt pathway involvement in cancer. The zebrafish (Danio rerio) offers several advantages: external development, optical clarity, and amenability to chemical screening. Transgenic zebrafish expressing GFP under a Wnt-responsive promoter allow real-time visualisation of Wnt activity during tumour development. Zebrafish xenografts of human cancer cells enable rapid assessment of Wnt inhibitor efficacy.

Mouse models remain the gold standard for cancer studies. The APC^Min mouse, harbouring a truncating mutation in Apc, develops multiple intestinal adenomas and is the most widely used model of familial adenomatous polyposis. Conditional knockout models using Cre-lox technology allow tissue-specific deletion of Wnt pathway components. For example, villin-Cre; Apc^fl/fl mice develop intestinal tumours within weeks, providing a rapid model for therapeutic testing.

Therapeutic Targeting of Wnt Signalling

The central role of Wnt signalling in cancer makes it an attractive therapeutic target. However, the pathway's complexity and its essential functions in normal adult tissues (particularly the intestinal epithelium) pose significant challenges. Nevertheless, multiple strategies are in various stages of preclinical and clinical development.

Porcupine Inhibitors

Porcupine is the O-acyltransferase required for Wnt ligand palmitoylation and secretion. Inhibiting Porcupine blocks all Wnt ligand secretion, effectively starving Wnt-dependent tumours of their growth factors. The most advanced Porcupine inhibitor is LGK974 (also known as WNT974), which has entered phase I clinical trials for Wnt-addicted cancers including pancreatic, colorectal, and head and neck cancers.

The mechanism of LGK974 involves covalent binding to Porcupine's active site serine residue, irreversibly inactivating the enzyme. Preclinical studies demonstrate that LGK974 suppresses tumour growth in mouse models of RNF43-mutant pancreatic cancer and APC-mutant colorectal cancer. The primary dose-limiting toxicity is bone toxicity, reflecting the role of Wnt signalling in osteoblast function.

Frizzled Antagonists

OMP-18R5 (vantictumab) is a fully human monoclonal antibody that binds multiple Frizzled receptors (FZD1, 2, 5, 7, 8), blocking Wnt ligand binding. By targeting multiple receptors, vantictumab broadly inhibits both canonical and non-canonical Wnt signalling. In preclinical models, vantictumab reduces tumour growth and cancer stem cell frequency.

A related approach uses soluble Frizzled-related proteins or Frizzled-CRD-Fc fusion proteins that act as "ligand traps," sequestering Wnt proteins in the extracellular space. OMP-54F28 (ipafricept) is a fusion protein consisting of the FZD8 cysteine-rich domain fused to the Fc region of human IgG1. It binds Wnt ligands with high affinity and prevents their interaction with cellular receptors. Both vantictumab and ipafricept have been evaluated in phase I trials, with bone-related toxicities again emerging as a common theme.

β-Catenin Inhibitors

Directly targeting β-catenin is challenging because it lacks enzymatic activity and its interaction surfaces are large and flat. Nevertheless, several strategies have emerged. The small molecule ICG-001 disrupts the interaction between β-catenin and the co-activator CBP (CREB-binding protein), selectively inhibiting Wnt-driven transcription. PRI-724, a related compound, has been tested in phase I/II trials for advanced solid tumours and liver cirrhosis.

Another approach targets the β-catenin/TCF interaction directly. Compounds such as PKF115-584 and CGP049090 bind β-catenin and prevent its association with TCF, thereby blocking transcriptional activation. These compounds show activity in preclinical models of colorectal cancer and multiple myeloma, although their clinical development has been limited by poor pharmacokinetics.

An emerging strategy exploits the ubiquitin-proteasome system by using proteolysis-targeting chimeras (PROTACs) that recruit E3 ligases to degrade β-catenin. These agents are in early preclinical development but represent a promising avenue for targeting the pathway's central effector.

Common Pitfalls and Misconceptions

Students frequently encounter conceptual difficulties when studying Wnt signalling. Understanding these common errors will help you avoid them in examinations and research.

Canonical vs Non-Canonical Confusion

The most frequent error is conflating the canonical and non-canonical pathways. Remember: canonical Wnt signalling is defined by β-catenin stabilisation and TCF/LEF-dependent transcription. Non-canonical pathways (PCP and Ca²⁺) operate independently of β-catenin. A useful mnemonic: "Canonical = β-catenin; Non-canonical = everything else."

It is also incorrect to assume that specific Wnt ligands exclusively activate one branch. While Wnt1, Wnt3a, and Wnt8 are typically canonical, and Wnt5a and Wnt11 are typically non-canonical, this is not absolute. The cellular context, receptor expression profile, and co-receptor availability determine the signalling outcome. In some cell types, Wnt5a can activate canonical signalling, and Wnt3a can activate non-canonical pathways.

β-Catenin Localization Interpretation

A second common error is misinterpreting β-catenin localisation. Nuclear β-catenin indicates active canonical Wnt signalling, but its absence from the nucleus does not necessarily mean the pathway is inactive. β-catenin can shuttle between cytoplasm and nucleus, and in some contexts, cytoplasmic accumulation without nuclear localisation may still contribute to oncogenic signalling through non-transcriptional mechanisms.

Conversely, nuclear β-catenin is not always indicative of cancer. During normal intestinal crypt homeostasis, nuclear β-catenin is present in stem cells at the crypt base. The distinction between physiological and pathological Wnt activation lies in the magnitude and persistence of signalling, not merely its presence.

Context-Dependent Roles of Wnt

A third misconception is that all Wnt signalling is oncogenic. In reality, Wnt pathway components can function as tumour suppressors in specific contexts. For example, Wnt5a, a non-canonical ligand, is downregulated in some cancers and can inhibit canonical Wnt signalling by promoting β-catenin degradation through a Siah2-dependent mechanism. Similarly, the Wnt antagonist DKK3 is silenced in many cancers, but its overexpression can promote apoptosis in some contexts.

The context-dependent nature of Wnt signalling is also evident in the differential effects of β-catenin on the Apoptosis Pathway. While β-catenin generally promotes survival by transactivating anti-apoptotic genes, in certain cellular contexts it can sensitise cells to apoptosis. This duality underscores the importance of considering the entire signalling network rather than individual components in isolation.

Summary and Exam Tips

Key Takeaways

Wnt signalling is a fundamental developmental pathway that, when dysregulated, drives cancer through constitutive β-catenin stabilisation and transcriptional activation.
The canonical pathway is controlled by the destruction complex (APC, Axin, GSK3β, CK1α), which phosphorylates β-catenin to mark it for proteasomal degradation.
Non-canonical Wnt pathways (PCP and Ca²⁺) operate independently of β-catenin and regulate cell polarity, migration, and cytoskeletal dynamics.
Colorectal cancer is the paradigm of Wnt-driven malignancy, with APC mutations in ~80% of cases and CTNNB1 mutations in a further subset.
Epigenetic silencing of Wnt antagonists (SFRPs, DKKs, WIF1) provides an alternative mechanism of pathway activation.
Wnt signalling maintains cancer stem cells, promotes angiogenesis, and suppresses anti-tumour immunity.
Therapeutic strategies include Porcupine inhibitors (LGK974), Frizzled antibodies (vantictumab), and β-catenin/CBP interaction inhibitors (ICG-001).
The pathway's essential roles in normal tissue homeostasis, particularly the intestinal epithelium, create therapeutic challenges that are being addressed through careful dose optimisation and combination strategies.

Exam Preparation Strategies

For examinations, focus on understanding the logic of the pathway rather than memorising every component. Draw the pathway from memory, including the destruction complex, Wnt-induced signalling, and nuclear transcription. Practice explaining the consequences of specific mutations (APC truncation, CTNNB1 exon 3 mutations, SFRP methylation) in terms of pathway activity.

Compare and contrast the canonical and non-canonical pathways in a table, noting ligands, receptors, co-receptors, downstream effectors, and cancer relevance. Understand why APC mutations are dominant at the cellular level but recessive at the genetic level (both alleles must be inactivated).

For therapeutic questions, be prepared to explain the rationale for each drug class, the mechanism of action, and the potential toxicities. Relate the toxicity profile to the normal physiological functions of Wnt signalling. Finally, connect Wnt signalling to other pathways you have studied, such as the Notch Signaling Pathway, JAK STAT Pathway, and P53 Pathway, as cross-talk between these pathways is frequently examined.

Frequently Asked Questions

What is the Wnt signalling pathway?

The Wnt signalling pathway is a conserved cell-to-cell communication system that regulates gene expression, cell proliferation, differentiation, polarity, and migration. It is activated by secreted Wnt glycoproteins binding to Frizzled receptors and co-receptors. The pathway has three main branches: the canonical Wnt/β-catenin pathway, the non-canonical Wnt/PCP pathway, and the non-canonical Wnt/Ca²⁺ pathway.

How does Wnt signalling contribute to cancer?

Wnt signalling contributes to cancer through constitutive activation of the canonical pathway, leading to persistent β-catenin/TCF transcriptional activity. This drives expression of genes promoting proliferation (MYC, CCND1), survival (Survivin), stemness (LGR5, SOX9), and invasion (MMP7, SNAIL). The pathway also maintains cancer stem cells, promotes angiogenesis, and suppresses anti-tumour immunity.

What is the role of β-catenin in Wnt signalling?

β-catenin is the central effector of canonical Wnt signalling. In unstimulated cells, it is phosphorylated by CK1α and GSK3β within the destruction complex and targeted for proteasomal degradation. Wnt stimulation inhibits this degradation, allowing β-catenin to accumulate and translocate to the nucleus, where it acts as a transcriptional co-activator for TCF/LEF transcription factors.

Which cancers are associated with Wnt signalling mutations?

Colorectal cancer has the highest frequency of Wnt pathway mutations (APC in ~80%, CTNNB1 in ~10%). Other cancers include hepatocellular carcinoma (CTNNB1 in ~15-30%), gastric cancer (APC and CTNNB1), pancreatic cancer (RNF43 mutations), endometrial cancer (CTNNB1), and certain leukaemias. Wnt pathway activation without mutations is even more widespread, occurring through epigenetic silencing of inhibitors.

What is the difference between canonical and non-canonical Wnt pathways?

The canonical pathway signals through β-catenin and TCF/LEF transcription factors, requiring LRP5/6 co-receptors. Non-canonical pathways are β-catenin-independent: the PCP pathway signals through RhoA/ROCK and Rac1/JNK to regulate cytoskeletal dynamics, while the Ca²⁺ pathway signals through PLC, IP₃, and calcium to activate PKC and NFAT.

How is Wnt signalling studied in the lab?

Common methods include TOP/FOP luciferase reporter assays to measure transcriptional activity, Western blotting for total and phosphorylated β-catenin, immunofluorescence or immunohistochemistry to assess β-catenin localisation, RT-qPCR for Wnt target genes, and genetic models including APC^Min mice and conditional knockout mice.

Are there drugs that target the Wnt pathway?

Yes, several classes of Wnt inhibitors are in development. Porcupine inhibitors (LGK974) block Wnt ligand secretion. Frizzled antibodies (vantictumab) and ligand traps (ipafricept) sequester Wnt ligands or block receptor binding. β-catenin/CBP interaction inhibitors (ICG-001, PRI-724) block transcriptional activity. Tankyrase inhibitors (XAV939) promote Axin stabilisation and destruction complex activity. Several agents have entered clinical trials, though none are yet FDA-approved for cancer treatment.